Cell Therapy | Manufacturing

Garnet BioTherapeutics has largely solved the issues associated with cost-effective commercial scalability, and this scalable manufacturing process produces a homogenous, pure and consistent cell product.  Cells are cultured in conditions optimized for cell growth/expansion, and the process does not involve immortalization of the cells or complicated and expensive additional ingredients. This process is GMP (FDA) compliant and has the capacity to produce more than sufficient clinical and commercial quantities of GBT 009.

In addition, our manufacturing process enables the production of potentially billions of doses of cells from a single human donor -- enough to supply the entire predicted marketplace for at least one, if not more, indications. This means that the product that is tested in clinical trials is the same for every patient and is the same product that will eventually be sold. This represents a significant advantage over competitive products, which must use cells derived from dozens if not hundreds of discrete donors.